NASDAQ:VLON Vallon Pharmaceuticals (VLON) Stock Price, News & Analysis → Elon Musk’s Controversial New Project: “Apollo” (From InvestorPlace) (Ad) Free VLON Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.43▼$0.4850-Day Range$0.27▼$2.8752-Week Range$0.21▼$12.92Volume143,177 shsAverage Volume5.78 million shsMarket Capitalization$6.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsInsider TradesSocial MediaStock AnalysisCompetitorsInsider TradesSocial Media Get Vallon Pharmaceuticals alerts: Email Address Ad InvestorPlaceElon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...Click here to see the details because there's a lot of money at stake. About Vallon Pharmaceuticals Stock (NASDAQ:VLON)Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.Read More Ad InvestorPlaceElon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...Click here to see the details because there's a lot of money at stake. VLON Stock News HeadlinesJuly 21, 2023 | forbes.comQuestcor Pharmaceuticals,April 20, 2023 | bizjournals.comVallon Pharmaceuticals' shareholders approve reverse merger with California companyApril 24, 2024 | InvestorPlace (Ad)Elon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...April 20, 2023 | finance.yahoo.comVallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock SplitApril 12, 2023 | finance.yahoo.comVallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023April 7, 2023 | bizjournals.comLab Notes: CHOP gets $10M research gift; Vallon seeks greater shareholder support for mergerApril 4, 2023 | finance.yahoo.comVallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ETFebruary 24, 2023 | finanznachrichten.deVallon Pharmaceuticals Inc.: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial ResultsApril 24, 2024 | InvestorPlace (Ad)Elon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...February 24, 2023 | finance.yahoo.comVallon Pharmaceuticals Reports Fiscal Year 2022 Financial ResultsFebruary 14, 2023 | benzinga.comIs Vallon Pharmaceuticals Inc (VLON) recent surge justifiedJanuary 11, 2023 | finance.yahoo.comVallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch EventDecember 27, 2022 | benzinga.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vallon Pharmaceuticals, Inc. - VLONDecember 14, 2022 | bizjournals.comVallon Pharmaceuticals to merge with California biotech firm in 'best path forward'December 14, 2022 | msn.comWhat's Going On With Vallon Pharmaceuticals Stock Today?December 14, 2022 | benzinga.comWhy Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving PremarketDecember 13, 2022 | finance.yahoo.comVallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell RegulatorsNovember 3, 2022 | finance.yahoo.comVallon Pharmaceuticals Reports Third Quarter 2022 Financial ResultsJuly 28, 2022 | finance.yahoo.comVallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateJuly 20, 2022 | finance.yahoo.comVallon Pharmaceuticals, Inc. (VLON)May 16, 2022 | bizjournals.comVallon Pharmaceuticals plans $3.9M stock sale to support exploration of strategic alternativesMay 13, 2022 | seekingalpha.comVallon Pharmaceuticals to raise $3.9M in stock offeringMay 13, 2022 | finance.yahoo.comVallon Pharmaceuticals Announces $3.9 Million Registered Direct OfferingMay 12, 2022 | finance.yahoo.comVallon Pharma Posts Additional Data From SEAL Study Of Formulated CNS StimulantMay 12, 2022 | finance.yahoo.comVallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIRMay 11, 2022 | finance.yahoo.comVallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIRMay 9, 2022 | finance.yahoo.comVallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateSee More Headlines Receive VLON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vallon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VLON CUSIPN/A CIK1824293 Webwww.vallon-pharma.com Phone267-607-8255FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,020,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-230.48% Return on Assets-124.89% Debt Debt-to-Equity RatioN/A Current Ratio2.29 Quick Ratio2.29 Sales & Book Value Annual Sales$100,000.00 Price / Sales60.25 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book2.48Miscellaneous Outstanding Shares13,482,000Free Float8,453,000Market Cap$6.03 million OptionableNot Optionable Beta-1.14 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. David C. Baker (Age 59)CEO, Pres & Director Comp: $553.55kMs. Leanne M. Kelly (Age 45)Chief Financial Officer Comp: $328.52kDr. Ofir Levi Ph.D. (Age 48)Consulting Dr. Timothy M. Whitaker (Age 63)Chief Medical Officer Key CompetitorsVaccinexNASDAQ:VCNXAvenue TherapeuticsNASDAQ:ATXIXenetic BiosciencesNASDAQ:XBIOHoth TherapeuticsNASDAQ:HOTHAyala PharmaceuticalsNASDAQ:ADXSView All Competitors VLON Stock Analysis - Frequently Asked Questions When did Vallon Pharmaceuticals' stock split? Shares of Vallon Pharmaceuticals reverse split before market open on Monday, April 24th 2023. The 1-30 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Vallon Pharmaceuticals IPO? Vallon Pharmaceuticals (VLON) raised $15 million in an IPO on Wednesday, February 10th 2021. The company issued 1,700,000 shares at $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. This page (NASDAQ:VLON) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vallon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
